Clinical Research Directory

Inclusion Criteria: * Patients diagnosed with Central Precocious Puberty presenting an indication to undertake treatment with GnRH analogue: Appearance of secondary sexual characteristics (thelarche or gonadarche) before the age of 8 for females and 9 for males; Acceleration of the rate of statural growth and advancement of bone age one year older than the chronological age; LH peak \> 5 IU/L on GnRH test and a longitudinal uterine diameter \> 36 mm in females, with or without the appearance of endometrial rhyme; * Age at onset of entral Precocious Puberty between 2 and 8 years (females) or between 2 and 9 years (males); * Age at enrollment \< 18 years; * Follow-up of at least 12 months; * Obtaining informed consent from parents/legal guardian of peduatric patients. Exclusion Criteria: * Isolated telarche and/or pubarche; * Peripheral forms of precocious puberty; * Patients diagnosed with primary organic Central Precocious Puberty due to tumour- or non-tumour-causing hypothalamic lesions.